K162167 is an FDA 510(k) clearance for the Caphosol Artifical Saliva Tablets. Classified as Saliva, Artificial (product code LFD).
Submitted by Eusa Pharma (Uk) Limited (Hemel Hempstead, GB). The FDA issued a Cleared decision on March 31, 2017 after a review of 240 days - an extended review cycle.
This device falls under the Dental FDA review panel. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Dental review framework, consistent with the majority of Class II 510(k) submissions.
View all Eusa Pharma (Uk) Limited devices